| Title |
New Disease-Modifying Therapies and New Challenges for MS
|
|---|---|
| Published in |
Current Neurology and Neuroscience Reports, July 2012
|
| DOI | 10.1007/s11910-012-0295-2 |
| Pubmed ID | |
| Authors |
Vijayshree Yadav, Dennis Bourdette |
| Abstract |
The availability of the second-generation therapies for relapsing multiple sclerosis (MS), natalizumab and fingolimod, provides new treatment options for MS but also presents new challenges. Both natalizumab and fingolimod appear to be more effective than the interferon beta products and glatiramer acetate, but both have more safety problems than do the first-generation therapies. Treatment with natalizumab is associated with a significant risk of patients developing progressive multifocal leukoencephalopathy (PML), which the JC virus causes. We now are able to risk stratify MS patients into high- and low-risk groups for developing PML on the basis of the presence or absence of antibodies to the JC virus, history of prior use of immunosuppressants, and duration of therapy with natalizumab. Fingolimod appears to be associated with a risk of asystole and sudden death. It may also increase the risk of serious herpes infections and paradoxical activation of MS. More information is needed about these serious side effects from fingolimod to allow us to use it safely in patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 19% |
| Student > Doctoral Student | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Other | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 5 | 16% |
| Unknown | 9 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 38% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Economics, Econometrics and Finance | 2 | 6% |
| Immunology and Microbiology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 10 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2014.
All research outputs
#6,992,485
of 22,919,505 outputs
Outputs from Current Neurology and Neuroscience Reports
#365
of 916 outputs
Outputs of similar age
#49,506
of 164,603 outputs
Outputs of similar age from Current Neurology and Neuroscience Reports
#7
of 19 outputs
Altmetric has tracked 22,919,505 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 916 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,603 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.